ReviewMolecular diagnosis & therapy2016
Follicle-Stimulating Hormone Receptor (FSHR): A Promising Tool in Oncology?
Review in Molecular diagnosis & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 45 citations in OpenAlex.
- Radiolabeled LHRH and FSH Analogues as Cancer Theranostic Agents: A Systematic Review.Journal of clinical medicine · 2025Review
- Biomimetic Nanoparticles Loaded With α-Cyperone Alleviating LPS-Induced Inflammation in KGN Cells by Activating Nrf2/HO-1 and Suppressing ROS.Journal of biochemical and molecular toxicology · 2025Article
- Article
- Modeling Host-Pathogen Interactions inInternational journal of molecular sciences · 2024Review
- Review
- Topoisomeric Membrane-Active Peptides: A Review of the Last Two Decades.Pharmaceutics · 2023Review
- Pilot Study: FSHR Expression in Neuroendocrine Tumors of the Appendix.Journal of clinical medicine · 2023Article
- Whole-genome sequencing identified novel mutations in a Chinese family with lynch syndrome.Frontiers in oncology · 2023Article
- A literature review of microvascular proliferation in arteriovenous malformations of skin and soft tissue.Journal of clinical and translational research · 2021Review
- Recent Applications of Retro-Inverso Peptides.International journal of molecular sciences · 2021Review
- Coping with DNA Double-Strand Breaks via ATM Signaling Pathway in Bovine Oocytes.International journal of molecular sciences · 2020Article
- Enhanced antitumor effects of follicle-stimulating hormone receptor-mediated hexokinase-2 depletion on ovarian cancer mediated by a shift in glucose metabolism.Journal of nanobiotechnology · 2020Article
- Glycoprotein G-protein Coupled Receptors in Disease: Luteinizing Hormone Receptors and Follicle Stimulating Hormone Receptors.Diseases (Basel, Switzerland) · 2020Review
- Genomic Characteristics and Selection Signatures in Indigenous Chongming White Goat (Frontiers in genetics · 2020Article
- Roles of follicle stimulating hormone and its receptor in human metabolic diseases and cancer.American journal of translational research · 2020Review
- Nanocomposites as biomolecules delivery agents in nanomedicine.Journal of nanobiotechnology · 2019Review
- Gain-of-Function Genetic Models to Study FSH Action.Frontiers in endocrinology · 2019Review
- FSH receptor binding inhibitor up-regulates ARID1A and PTEN genes associated with ovarian cancers in mice.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2019Article
- Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy.Drug delivery · 2018Article
- Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-α silencing and antitumor activity against ovarian cancer.Drug delivery · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cellular pathway of follicle-stimulating hormone (FSH) and its receptor (FSHR) is typically involved in reproduction in mammals. In humans, the FSHR is normally found in cells of the testis and the ovary, while it is scarcely expressed in other normal tissues. The expression of FSH/FSHR is studied in prostate, thyroid, and ovarian cancer tissues. Recently, the expression of FSHR was uniformly documented in malignant vascular endothelial cells from different tumor types, while in normal or inflammatory tissues its expression was scarce, suggesting a potential role of a pan-receptor in cancer. Subsequent studies have attempted to verify this unique specificity of this molecule and further define its features in malignant microenvironments but have had conflicting results, mostly because of differing techniques and immaturity of antibodies. Still, the lack of FSHR expression in most non-cancerous cells, in contrast to its specific correlation with the malignant tissue microenvironment, implies a potential role as both a diagnostic and a therapeutic tool. FSHR might also have a very specific role in malignancies, such as angiogenic and/or growth factor malignancies, but this is yet to be validated. Moreover, the expression of FSHR in endothelial malignant cells could have a predictive impact on disease progression, especially in relation to therapies targeting the tumor vasculature. In this review we look deep into the physiology of the FSH/FSHR pathway and evaluate the potential of FSHR as a predictive and prognostic tool in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.